148 related articles for article (PubMed ID: 20364021)
21. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
22. Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Strowd RE; Blackwood R; Brown M; Harmon M; Lovato J; Yalcinkaya T; Lesser G
J Oncol Pharm Pract; 2013 Dec; 19(4):321-7. PubMed ID: 23292971
[TBL] [Abstract][Full Text] [Related]
23. Single vs. combination immunotherapeutic strategies for glioma.
Chandran M; Candolfi M; Shah D; Mineharu Y; Yadav VN; Koschmann C; Asad AS; Lowenstein PR; Castro MG
Expert Opin Biol Ther; 2017 May; 17(5):543-554. PubMed ID: 28286975
[TBL] [Abstract][Full Text] [Related]
24. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Kim CH; Woo SJ; Park JS; Kim HS; Park MY; Park SD; Hong YK; Kim TG
Immunology; 2007 Dec; 122(4):615-22. PubMed ID: 17645496
[TBL] [Abstract][Full Text] [Related]
25. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
[TBL] [Abstract][Full Text] [Related]
26. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
Yokota C; Kagawa N; Takano K; Chiba Y; Kinoshita M; Kijima N; Oji Y; Oka Y; Sugiyama H; Tsuboi A; Izumoto S; Kishima H; Hashimoto N
Cancer Immunol Immunother; 2022 Jan; 71(1):189-201. PubMed ID: 34089373
[TBL] [Abstract][Full Text] [Related]
27. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
[TBL] [Abstract][Full Text] [Related]
28. [Glioma therapy up-date].
de la Fuente BP; Dalmau J; Rosenfeld M
Neurologia; 2007 Apr; 22(3):159-69. PubMed ID: 17364254
[TBL] [Abstract][Full Text] [Related]
29. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
Nakajima H; Oka Y; Tsuboi A; Tatsumi N; Yamamoto Y; Fujiki F; Li Z; Murao A; Morimoto S; Hosen N; Shirakata T; Nishida S; Kawase I; Isaka Y; Oji Y; Sugiyama H
Vaccine; 2012 Jan; 30(4):722-9. PubMed ID: 22133512
[TBL] [Abstract][Full Text] [Related]
30. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Harris MT; Rosenthal MA; Ashley DL; Cher L
J Clin Neurosci; 2001 Jul; 8(4):325-7. PubMed ID: 11437571
[TBL] [Abstract][Full Text] [Related]
31. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Chaskis C; Neyns B; Michotte A; De Ridder M; Everaert H
Surg Neurol; 2009 Oct; 72(4):423-8. PubMed ID: 19150114
[TBL] [Abstract][Full Text] [Related]
32. A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia.
Kobayashi Y; Sakura T; Miyawaki S; Toga K; Sogo S; Heike Y
Cancer Immunol Immunother; 2017 Jul; 66(7):851-863. PubMed ID: 28321480
[TBL] [Abstract][Full Text] [Related]
33. WT1 peptide vaccine for the treatment of cancer.
Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
[TBL] [Abstract][Full Text] [Related]
34. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK
Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936
[TBL] [Abstract][Full Text] [Related]
35. Effects of palliative treatment with temozolomide in patients with high-grade gliomas.
Ziobro M; Rolski J; Grela-Wojewoda A; Zygulska A; Niemiec M
Neurol Neurochir Pol; 2008; 42(3):210-5. PubMed ID: 18651326
[TBL] [Abstract][Full Text] [Related]
36. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
37. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
[TBL] [Abstract][Full Text] [Related]
38. Is protracted low-dose temozolomide feasible in glioma patients?
Wong ET
Neurology; 2006 Aug; 67(3):543-4; author reply 543-4. PubMed ID: 16894133
[No Abstract] [Full Text] [Related]
39. Peptide vaccine.
Izumoto S
Adv Exp Med Biol; 2012; 746():166-77. PubMed ID: 22639167
[TBL] [Abstract][Full Text] [Related]
40. [WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers].
Kato Y
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2240-2. PubMed ID: 21224534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
